Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus

Novartis

Status and phase

Completed

Phase 4

Conditions

Hypertension

Treatments

Drug: Amlodipine/benazepril

Study type

Interventional

Funder types

Industry

Identifiers

NCT00367978

CCIB002FUS06

Details and patient eligibility

About

This study evaluated the efficacy and safety of amlodipine/benazepril compared with that of enalapril in the treatment of hypertension in African-American patients with type 2 diabetes.

Enrollment

275 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

African-American
males and females
current diagnosis of type 2 diabetes documented by medical history;
mean sitting diastolic blood pressure of ≥ 90 and ≤ 110 mm Hg;
HbA1C ≤ 9.5%

Exclusion criteria

having unilateral or bilateral renal artery stenosis;
having clinically significant cardiac dysrhythmias;
having a significant history of coronary artery disease within the past 6 months;
having a history or diagnosis of congestive heart failure (CHF);
having any clinically relevant cardiac valvular disease